HC Wainwright Predicts Higher Earnings for LENZ Therapeutics

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – Stock analysts at HC Wainwright increased their FY2029 earnings per share estimates for shares of LENZ Therapeutics in a report issued on Thursday, May 8th. HC Wainwright analyst M. Caufield now anticipates that the company will post earnings per share of $1.52 for the year, up from their prior estimate of $1.45. HC Wainwright currently has a “Buy” rating and a $38.00 price target on the stock. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share.

Several other analysts also recently weighed in on LENZ. Citigroup lifted their price target on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the company a “buy” rating in a research note on Thursday, March 20th. TD Cowen initiated coverage on LENZ Therapeutics in a research report on Tuesday, March 18th. They set a “buy” rating and a $60.00 price target on the stock. Finally, Piper Sandler started coverage on shares of LENZ Therapeutics in a research note on Monday, April 14th. They issued an “overweight” rating and a $51.00 price objective for the company. Five research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $46.60.

LENZ Therapeutics Price Performance

LENZ Therapeutics stock opened at $26.34 on Friday. The stock has a market cap of $725.54 million, a price-to-earnings ratio of -5.52 and a beta of 0.41. The firm has a 50-day moving average of $24.56 and a two-hundred day moving average of $27.28. LENZ Therapeutics has a 1 year low of $14.42 and a 1 year high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last issued its earnings results on Wednesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.02.

Institutional Trading of LENZ Therapeutics

A number of institutional investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. purchased a new stake in LENZ Therapeutics during the fourth quarter valued at approximately $29,000. KLP Kapitalforvaltning AS acquired a new position in shares of LENZ Therapeutics during the fourth quarter worth $46,000. Tower Research Capital LLC TRC lifted its holdings in shares of LENZ Therapeutics by 162.3% during the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company’s stock valued at $54,000 after purchasing an additional 1,151 shares during the last quarter. Virtus ETF Advisers LLC acquired a new stake in shares of LENZ Therapeutics in the 4th quarter worth $67,000. Finally, GAMMA Investing LLC grew its stake in LENZ Therapeutics by 5,254.1% during the 1st quarter. GAMMA Investing LLC now owns 5,836 shares of the company’s stock worth $150,000 after buying an additional 5,727 shares during the last quarter. 54.32% of the stock is currently owned by institutional investors.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.